X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Teijin will receive exclusive license to further develop and commercialize TransCon hGH (lonapegsomatropin-tcgd), TransCon PTH, and TransCon CNP for endocrinology rare disease, in Japan.
Lead Product(s): Lonapegsomatropin
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Ascendis Pharma
Deal Size: $245.0 million Upfront Cash: $70.0 million
Deal Type: Licensing Agreement November 29, 2023
Details:
Teijin will grant Novartis exclusive worldwide rights to research, develop, manufacture and commercialize an investigational small molecule candidate for proteinuric kidney diseases. The candidate is believed to impact the pathogenesis of multiple kidney diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undislcosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $230.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement March 06, 2023
Details:
Xeomin ® is effective in the treatment of peripheral cholinergic nerve endings by decreasing the contraction of voluntary muscles, and relieves muscle tone by inhibiting the release of a neurotransmitter, acetylcholine.
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merz Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2021
Details:
The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Lead Product(s): Alogliptin Benzoate,Pioglitazone
Therapeutic Area: Endocrinology Product Name: Liovel
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 01, 2021
Details:
The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Lead Product(s): Alogliptin Benzoate
Therapeutic Area: Endocrinology Product Name: Nesina
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Divestment February 26, 2021
Details:
Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: TransThera Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
